2004 Volume 114 Issue 9 Pages 1517-1527
We treated several skin diseases with narrowband UVB (NB-UVB) and UVA1. NB-UVB was used to treat patients with psoriasis, plaque type parapsoriasis, and vitiligo, and UVA1 was used to treat patients with atopic dermatitis and prurigo nodularis. We adopted 0.5 J/cm2 and 5.0 J/cm2 as starting doses for NB-UVB and UVA1, respectively. In order to avoid overdose, the increment of the doses were 0.1 J/cm2 for NB-UVB therapy and 1.0 J/cm2 for UVA1 therapy. Results were more successful when the treatment was administered twice a week. Positive effects (67–99% improvement) were achieved in 38.6% of psoriasis patients, in 100% of plaque type parapsoriasis patients, in 37.5% of vitiligo patients (NB-UVB), in 47.1% of atopic dermatitis patients, and in 71.5% of prurigo nodularis patients (UVA1). There were no severe side effects during these treatment periods.
